Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T-19 Injection for Relapsed/Refractory B-cell ALL
NCT06179524Phase 2Recruiting
- Sponsor
- Immunotech Biopharm
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CAR-T-19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Immunotech Biopharm. Started Jan 2024; status: recruiting.
02
Drugs
CAR-T-19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06179524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179524.